Urinary catheterization

Syringes, Needles, and Urinary Catheters Market Forecast to 2033, by Size, Segments, Share, Regulatory, Reimbursement and Procedures - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 27, 2023
Biotechnology, Medical Devices, Health, Health Technology, Medical Supplies, Epidemiology, Urine, Cardiac catheterization, Patient, Procedure, Urinary catheterization, Needle, Market access, Internet, Urinary incontinence, Urinary retention

The "Syringes, Needles, and Urinary Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syringes, Needles, and Urinary Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • Urinary catheters are used to treat patients with urinary incontinence, urinary retention, or other urological disorders.
  • Urinary catheters include indwelling (Foley) catheter, intermittent (short term) catheter, and external (condom) catheter.
  • Annualized total Syringes, Needles, and Urinary Catheters market revenue by segment and market outlooks from 2015-2033.

BetterCaths Coalition Assists Rep. Josh Turek in Designing Better Caths for Iowa Act to Remove Harmful Phthalate Chemical DEHP From Urological Catheters

Retrieved on: 
Sunday, February 26, 2023
Allergy, Parkinson's disease, SCI/D, Cauda equina, Catheter, Learning, Cancer, Patient, Tokyo, Prostate cancer, Mortality, Iowa House of Representatives, Medicaid, Survivor, Organization, National Transportation Safety Board, Transverse myelitis, Bladder cancer, Health equity, Spina bifida, PVC, Norfolk Southern Railway, Legislation, Dementia, Cardiac catheterization, DEHP, Vinyl chloride, Human, Disability, Polyvinyl chloride, Australian Transport Safety Bureau, United Spinal Association, Asthma, Insulin resistance, Multiple sclerosis, Phthalate, Stroke, Urinary catheterization, Language, Medical device, Pharmaceutical industry, Dietary supplement, Medical imaging, Tokyo Paralympics

The Better Caths for Iowa Act is the first piece of legislation in the country that aims to lower the bladder cancer mortality rate for people whose lives depend on using urological catheters.

Key Points: 
  • The Better Caths for Iowa Act is the first piece of legislation in the country that aims to lower the bladder cancer mortality rate for people whose lives depend on using urological catheters.
  • It also protects Iowa Medicaid patients from daily exposure to the toxic chemical (DEHP) in some commonly-used urinary catheters.
  • The BetterCaths for Iowa Act places an immediate ban on Iowa Medicaid reimbursement of catheters that have known carcinogen warning labels.
  • It also requires Iowa Medicaid to review the historical bladder cancer rate and correlating brands of catheters used by their patients.

Bactiguard receives first MDR product approval

Retrieved on: 
Tuesday, January 10, 2023
Medical device, LaTeX, Catheter-associated urinary tract infection, MDR, Bacteria, HAI, Risk, Metal, Patient, Safety, Urinary catheterization, BIP, CAUTI, Patient safety

STOCKHOLM, Jan. 10, 2023 /PRNewswire/ -- Bactiguard today announces its first MDR (Medical Device Regulations 2017/745) product approval following a comprehensive authorization process.

Key Points: 
  • STOCKHOLM, Jan. 10, 2023 /PRNewswire/ -- Bactiguard today announces its first MDR (Medical Device Regulations 2017/745) product approval following a comprehensive authorization process.
  • The MDR approval relates to the latex BIP Foley Catheter which is an indwelling urinary catheter with Bactiguard's unique infection prevention technology.
  • Bactiguard's patented technology is based on a thin noble metal alloy coating attached to the catheter surface.
  • - Patient safety always comes first for Bactiguard, and stricter regulations are an advantage to us.

Prodeon Medical, Inc., Announces Randomization in the Expander-2 Pivotal Clinical Trial Evaluating the Company's Investigational Treatment for Lower Urinary Tract Symptoms Associated to Benign Prostatic Hyperplasia

Retrieved on: 
Monday, September 26, 2022
Urinary catheterization, Safety, Journal, Research, Anesthesia, Compliance, Loyola University, Patient, Virginia Tech Carilion School of Medicine and Research Institute, Technology, NCT, Prostate, Control, Kidney, BPH, Prostate cancer, Time, Common, Bleeding, Sale, Coronavirus Scientific Advisory Board (Turkey), Man, Depression, Burn, Dizziness, Time-invariant system, Prostatic urethral lift, Woman, LUTS, Efficacy, Stritch School of Medicine, CEO, Sexual dysfunction, Cystoscopy, Incontinence, Department, Headache, Quality of life, Dementia, PURE, The Indwelling, Pharmaceutical industry, Medical imaging, TURP, Urology

BPH is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to LUTS.

Key Points: 
  • BPH is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to LUTS.
  • The interim results of the EXPANDER-1 trial were recently published in the Journal of Prostate Cancer and Prostate Diseases [The EXPANDER-1 trial: introduction of the novel Urocross Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)].
  • Within the Expander-2 Trial, the Urocross Expander System and Retrieval Sheath will be used in a newly developed procedure called PURE (Prostatic Urethral REshaping) to relieve symptoms associated with BPH.
  • The Urocross Expander System and Urocross Retrieval Sheath are investigational devices and are not for sale in the US or outside the US.

Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

Retrieved on: 
Monday, November 8, 2021
Securities Exchange Act of 1934, Milk, Bone marrow, Nursing, View, Pregnancy, Industry, USP, Acceleration, Organization, Mother, Urinary catheterization, Leukopenia, Multimedia, Research, Securities Act of 1933, Fetus, Regulation, Twitter, Bone pain, Chloride, Market share, LinkedIn, Solution, Radioactive decay, SEC, Drug Quality and Security Act, Toxicity, Woman, Clothing, Physician, Bone, Analgesic, Patent, Patient, Risk, Medicine, Pharmaceutical industry, Birth control, Medical imaging

Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.

Key Points: 
  • Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • The nadir of platelet depression in most patients is found between 12- and 16-weeks following administration of Strontium-89 Chloride Injection.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend

Retrieved on: 
Tuesday, September 28, 2021
Securities Act of 1933, OTCQB, Pain, Safety, Radioactive decay, Fetus, SEC, Radiation, Clothing, Chloride, Drug Quality and Security Act, Nursing, Physician, Leukopenia, U.S. Department of Veterans Affairs, Office of Inspector General, Analgesic, USP, Cancer, Breast, Woman, Regulation, Bone marrow, Bone, FDA, Pregnancy, Kidney, Toxicity, Marketing, Mother, Risk, United States Department of Defense, Forward-looking statement, Acceleration, Department, Adoption, Patent, Bone pain, Patient, Formulary, Department of Defence, Lung cancer, Environment, Prostate cancer, Radiopharmaceutical, Milk, Prostate, Military personnel, U.S. Department of Defense Strategy for Operating in Cyberspace, Research, Urinary catheterization, Securities Exchange Act of 1934, Chills, Pharmaceutical industry, Medical imaging, Birth control, Medicine

These patients are now also able to benefit from Strontium89 treatment for their metastatic bone pain.

Key Points: 
  • These patients are now also able to benefit from Strontium89 treatment for their metastatic bone pain.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Strontium-89 Chloride Injection.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

Retrieved on: 
Tuesday, August 10, 2021
Breast, Pregnancy, Milk, Wilms' tumor, Acceleration, Radiation, INT, Woman, Radiopharmaceutical, Mother, Safety, Patient, Toxicity, Angleton, Pain, Physician, MacEwen, Risk, Thornburg Investment Management, Inc., Radioactive decay, OTCQB, Bone, Solution, Cancer, USP, Bone marrow, Leukopenia, Chills, Bone pain, Prostate, Analgesic, Lung, LLC, Nursing, Chloride, Environment, Awareness, STRONTIUM, Nuclear medicine, Clothing, Common, Fetus, FDA, Marketing, Urinary catheterization, Kidney, Pharmaceutical industry, Medical imaging, Dentistry, Birth control, Medicine

Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.

Key Points: 
  • Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.
  • isoSolutions and Q BioMed will work together to increase the awareness of doctors and patients to the availability of Strontium89.
  • Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in Canadaas well as in other markets worldwide.
  • We are happy to collaborate with isoSolutions and provide patients in Canada with Strontium89, a viable treatment for patients suffering from painful skeletal metastases caused by cancer."

Global Syringes, Needles, and Urinary Catheters (Hospital Supplies) Market Report 2021: Analysis and Forecast Model with COVID-19 Market Impacts - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Medical Supplies, Health, Medicine, Medical specialties, Clinical medicine, Urology, Medical equipment, Surgical specialties, Drug paraphernalia, Urinary incontinence, Catheter, Urinary catheterization, Syringe, Urinary system

The "Syringes, Needles, and Urinary Catheters (Hospital Supplies) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syringes, Needles, and Urinary Catheters (Hospital Supplies) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses the effect of COVID -19 on the Syringes, Needles, and Urinary Catheters market for the year 2020 and beyond.
  • Urinary catheters are used to treat patients with urinary incontinence, urinary retention, or other urological disorders.
  • Track device sales in the global and country-specific Syringes, Needles, and Urinary Catheters market from 2015-2030.

InventHelp Inventor Develops Accessory for Urinary Catheter Collection Bags (ORD-2862)

Retrieved on: 
Monday, February 1, 2021
Medicine, Clinical medicine, Medical specialties, Catheters, Urology, Urinary catheterization, Urinary bladder, Foley catheter, Toileting

PITTSBURGH, Feb. 1, 2021 /PRNewswire/ -- "My sister had bladder surgery and needed a hands-free way to transport her urinary catheter collection bag," said an inventor, from Satsuma, Fla., "so I invented the patent-pending SISTER SHELF.

Key Points: 
  • PITTSBURGH, Feb. 1, 2021 /PRNewswire/ -- "My sister had bladder surgery and needed a hands-free way to transport her urinary catheter collection bag," said an inventor, from Satsuma, Fla., "so I invented the patent-pending SISTER SHELF.
  • The invention provides an improved way to store and transport a urinary catheter collection bag.
  • In doing so, it eliminates the need for a patient to carry an attached urinary catheter collection bag.
  • It allows medical staff to locate the urinary catheter collection bag quickly.

Urinary Catheters Market Size Worth $7.94 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Monday, January 11, 2021
Medicine, Catheters, Urology, Urinary catheterization

The advent of technologically advanced products is also expected to drive market growth.

Key Points: 
  • The advent of technologically advanced products is also expected to drive market growth.
  • For instance, RIOCATH - a Reversal Inside Out Catheterization, developed by Riocath global in collaboration with IOCB Prague, reduces the chances of infections in the body.
  • Based on product types, the market is divided into intermittent, foley/indwelling, and external catheters.
  • Grand View Research has segmented the global urinary catheters market on the basis of product, application, and region:
    Urinary Catheters Product Outlook (Revenue, USD Million, 2016 - 2028)